Entacapone (Comtan) is a reversible, selective catechol-O-methyltransferase (COMT) inhibitor that serves as a critical adjunct therapy in the treatment of Parkinson's disease. Developed to address the pharmacokinetic limitations of levodopa, entacapone has become a cornerstone of modern dopaminergic therapy since its FDA approval in 1998. [@schapira2007]
The drug works by blocking the COMT enzyme in the periphery, preventing the methylation and subsequent degradation of levodopa before it can cross the blood-brain barrier. This mechanism results in increased levodopa bioavailability, prolonged plasma half-life, and more stable dopaminergic stimulation in the brain. [@nutt1994]
| Property | Value |
|---|---|
| Drug Class | COMT Inhibitor |
| Approval Status | FDA Approved (1998), EMA Approved (1998) |
| Brand Names | Comtan ( Novartis), Stalevo (levodopa/carbidopa/entacapone combination) |
| Mechanism | Reversible, selective COMT inhibition (peripheral) |
| Route of Administration | Oral |
| Half-life | 0.5-2 hours |
| Bioavailability | ~35% |
| Protein Binding | ~30% |
| Elimination | Fecal (~90%), Renal (~10%) |
The catechol-O-methyltransferase enzyme plays a central role in the peripheral metabolism of levodopa, the precursor to dopamine. When levodopa is administered orally, it is absorbed in the small intestine and transported to the brain. However, a significant portion of each dose is metabolized by aromatic L-amino acid decarboxylase (AADC) in the periphery to dopamine, and by COMT to 3-O-methyldopa (3-OMD). This peripheral metabolism reduces the amount of levodopa available to cross the blood-brain barrier, necessitating higher doses and more frequent administration. [@kieburtz1998]
COMT is particularly important in the final stages of levodopa metabolism. When AADC is saturated (as occurs with standard levodopa/carbidopa therapy), COMT becomes the dominant pathway for levodopa clearance. The enzyme catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to the catechol moiety of levodopa, producing 3-OMD, which has a longer half-life than levodopa itself and can accumulate with chronic dosing. [@myllyl1998]
Entacapone enhances levodopa therapy through multiple pharmacodynamic mechanisms: [@rinne1998]
Peripheral COMT Inhibition: Entacapone binds reversibly to the active site of COMT, blocking its catalytic activity. This inhibition is selective for peripheral COMT, as the drug does not significantly cross the blood-brain barrier at therapeutic doses.
Increased Levodopa Bioavailability: By preventing levodopa conversion to 3-OMD, entacapone increases the fraction of each dose that reaches the brain. Studies show a 35-65% increase in levodopa AUC (area under the concentration-time curve).
Enhanced Brain Delivery: The increased plasma levodopa concentration gradient promotes greater transport across the blood-brain barrier via the large neutral amino acid transporter (LAT1).
Prolonged Half-life: Entacapone extends levodopa plasma half-life from approximately 1-1.5 hours to 2.5-3.5 hours, a 2-3 fold increase.
Reduced "Off" Time: More stable plasma levodopa levels translate to more continuous dopaminergic stimulation, reducing the time spent in the "off" state.
Reduced Daily Levodopa Dose: Many patients can maintain therapeutic benefit with reduced total daily levodopa doses.
The duration of COMT inhibition with entacapone is approximately 8 hours, corresponding to its dosing interval when administered with each levodopa dose. The enzyme inhibition is reversible, with COMT activity returning to baseline within 24 hours after the last dose. This reversibility distinguishes entacapone from the irreversible MAO-B inhibitors (selegiline, rasagiline) used in PD therapy. [@fnelon2005]
Entacapone is indicated as an adjunct to levodopa/carbidopa therapy in patients with Parkinson's disease who experience end-of-dose motor fluctuations ("wearing-off" phenomenon). The primary clinical benefits include: [@brooks2003]
Motor Fluctuation Management:
Wearing-Off Phenomenon:
Entacapone is particularly effective for patients with documented end-of-dose wearing off, where the beneficial effects of each levodopa dose diminish before the next dose is due. By prolonging levodopa availability, entacapone smooths out the fluctuations.
Advanced PD:
In patients with more advanced disease and significant motor complications, entacapone becomes an essential component of optimized dopaminergic therapy, often used in combination with dopamine agonists and MAO-B inhibitors.
Levodopa/Carbidopa/Entacapone (Stalevo):
The fixed-dose combination (trade name Stalevo in the US, Stalevo or Levodopa/Carbidopa/Entacapone generically) offers several advantages: [@ferreira2017]
Dosing Considerations:
| Parameter | Value | Clinical Significance |
|---|---|---|
| Absorption | Rapid, Tmax ~1 hour | Take with levodopa dose |
| Bioavailability | ~35% (reduced with food) | Take on empty stomach |
| Protein Binding | ~30% | Low risk of displacement interactions |
| Metabolism | Minimal hepatic (glucuronidation) | Safe in mild-moderate hepatic impairment |
| Half-life | 0.5-2 hours | Match to levodopa dosing |
| Duration of Effect | ~8 hours | Dose with each levodopa dose |
| Elimination | Fecal (~90%), Renal (~10%) | Monitor in severe renal impairment |
| Interacting Drug | Effect | Management |
|---|---|---|
| Non-selective MAOIs (phenelzine, tranylcypromine) | Contraindicated - risk of hypertensive crisis | Avoid combination |
| Selective MAO-B inhibitors (selegiline, rasagiline) | Generally safe - complementary mechanisms | Standard dosing |
| Apomorphine | May require dose adjustment of levodopa | Monitor response |
| Cholestyramine | Reduced entacapone absorption | Separate by 2+ hours |
| Iron supplements | Reduced entacapone absorption due to chelation | Separate by 2-3 hours |
| Anticholinergics | No significant interaction | Standard dosing |
| Domperidone | May affect absorption | Monitor timing |
Hepatic Impairment:
Renal Impairment:
Elderly:
Pregnancy: Category C - use only if benefit outweighs risk
Many side effects are related to the enhanced dopaminergic effect rather than entacapone itself: [@kieburtz1998]
Dyskinesia (most common):
Gastrointestinal:
Urine Discoloration:
Other:
Severe Diarrhea:
Hallucinations:
Orthostatic Hypotension:
Entacapone has a favorable safety profile compared to tolcapone:
Rinne et al. (1998) - First pivotal trial: [@rinne1998]
Kieburtz et al. (1998) - CONVERT Trial: [@kieburtz1998]
Brooks et al. (2003) - Long-term extension: [@brooks2003]
Large meta-analyses confirm:
| Feature | Entacapone | Opicapone | Tolcapone |
|---|---|---|---|
| Selectivity | Peripheral only | Peripheral only | Central + peripheral |
| Binding | Reversible | Irreversible | Reversible |
| Dosing | With each levodopa dose (up to 8x/day) | Once daily | 3-4x daily |
| Efficacy | Moderate | High (2x entacapone) | Highest |
| Liver toxicity | None | None | Requires monitoring |
| Discontinuation rate | ~15% | ~10% | ~30% |
| Cost | Moderate | Higher | Lower (generic) |
Opicapone is a newer COMT inhibitor approved in 2015: [@ferreira2017]
Tolcapone was the first COMT inhibitor (1997) but is now rarely used:
Ideal Candidates:
Consider Alternatives:
Entacapone acts as a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), the enzyme responsible for the peripheral metabolism of levodopa. The drug exhibits competitive inhibition with a Ki value of approximately 120 nM, meaning it binds to the enzyme's active site with high affinity while allowing the enzymatic reaction to reverse when the drug is cleared. [@stocchi2010]
The inhibition kinetics result in several important clinical characteristics:
Dose-Dependent Inhibition: At standard doses (200mg with each levodopa dose), entacapone achieves approximately 60-75% inhibition of peripheral COMT activity, which is sufficient to produce clinically meaningful increases in levodopa bioavailability. [@poewe2006]
Rapid Onset and Offset: Entacapone's reversible binding means that COMT activity returns to baseline within 4-6 hours after the last dose, requiring administration with each levodopa dose for continuous effect. [@ovall2004]
Selectivity: Unlike tolcapone, entacapone does not significantly cross the blood-brain barrier, providing peripheral COMT inhibition without central effects. This selectivity avoids potential central nervous system side effects and preserves the ability to use other COMT inhibitors in the future. [@schapira2007]
The addition of entacapone to levodopa/carbidopa therapy produces predictable changes in levodopa pharmacokinetics:
| Parameter | Without Entacapone | With Entacapone | Change |
|---|---|---|---|
| Cmax (ng/mL) | ~2.0 | ~3.0 | +50% |
| AUC (ng·h/mL) | ~8.0 | ~14.0 | +75% |
| Tmax (hours) | ~1.0 | ~0.8 | -20% |
| Half-life (hours) | ~1.5 | ~2.5 | +67% |
These changes result from the inhibition of the primary pathway for levodopa elimination (O-methylation), forcing more levodopa to reach the brain and extend its therapeutic effect. [@nutt1994]
The efficacy of entacapone was established through several pivotal randomized controlled trials:
SEESAW (Study on the Effects of Entacapone in Parkinson's Disease)
This double-blind, placebo-controlled study enrolled 172 patients with Parkinson's disease experiencing motor fluctuations. Patients were randomized to receive entacapone (200mg) or placebo with each levodopa dose for 24 weeks. The primary endpoint was change in "off" time, measured by patient diaries.
Results demonstrated a significant reduction in "off" time of approximately 1.4 hours per day in the entacapone group compared to baseline, versus minimal change in the placebo group. This translated to a mean increase in "on" time of similar magnitude, with improved motor function scores. [@kieburtz1998]
Long-Term Extension Studies
Several open-label extension studies followed patients for up to 5 years, demonstrating:
[@brooks2003]
Head-to-head comparisons with other COMT inhibitors reveal important distinctions:
Entacapone vs. Tolcapone
While both drugs inhibit COMT, they differ significantly in their properties:
| Feature | Entacapone | Tolcapone |
|---|---|---|
| COMT Selectivity | Peripheral only | Peripheral + Central |
| Dosing Frequency | With each levodopa dose | 3-4 times daily |
| Liver Toxicity | None reported | Requires LFT monitoring |
| Efficacy | Moderate | Highest |
| Tolerability | Better | Requires close monitoring |
Tolcapone provides slightly greater efficacy due to central COMT inhibition but requires more intensive monitoring for hepatotoxicity. Entacapone offers a more favorable safety profile while still providing meaningful clinical benefit. [@schapira2007]
Entacapone vs. Opicapone
Opicapone, a newer COMT inhibitor approved in Europe and the US, offers once-daily dosing with enhanced COMT inhibition:
| Feature | Entacapone | Opicapone |
|---|---|---|
| Dosing | With each levodopa dose | Once daily |
| COMT Inhibition | 60-75% | 80-90% |
| Off-time Reduction | ~1-2 hours/day | ~2-3 hours/day |
| Approval | FDA 1998 | FDA 2020 |
[@ferreira2017]
Entacapone is particularly appropriate for patients who meet the following criteria:
Established Motor Fluctuations: Patients experiencing "wearing-off" phenomena, where the duration of symptom relief from each levodopa dose becomes progressively shorter. [@larsen2009]
Inadequate Response to Levodopa Monotherapy: Patients whose symptoms are not adequately controlled despite optimized levodopa dosing.
Desire to Maintain Oral Therapy: Patients who wish to avoid more invasive treatments such as continuous infusion or deep brain stimulation.
Absence of Severe Dyskinesia: Patients who can tolerate increased dopaminergic stimulation without problematic dyskinesia exacerbation.
The question of when to introduce entacapone remains debated in the field. Earlier initiation may provide advantages, though later introduction remains common practice.
Early Introduction (Hoehn & Yahr Stage 1-2)
Arguments for early use include:
[@requena2010]
Later Introduction (Hoehn & Yahr Stage 3+)
Arguments for later use include:
Most clinicians introduce entacapone when motor fluctuations become clinically significant, typically after 3-5 years of levodopa therapy. [@jankovic2005]
The COMT enzyme is encoded by the COMT gene, which has well-characterized polymorphisms that affect enzyme activity:
Val158Met Polymorphism
The most studied COMT variant is the Val158Met (rs4680) single nucleotide polymorphism, which results in a 3-4 fold difference in enzyme activity:
This polymorphism may influence individual response to entacapone therapy. Patients with the Val/Val genotype may derive greater benefit from COMT inhibition due to their inherently higher COMT activity. [@nissinen2012]
While pharmacogenetic testing is not routinely performed, understanding these variations may guide therapy:
Elderly patients with Parkinson's disease require special consideration when using entacapone:
Considerations:
Dosing Recommendations:
While entacapone is not significantly metabolized by the liver, caution is advised in patients with severe hepatic impairment:
Entacapone elimination is primarily through feces, making renal impairment less concerning:
Multiple studies have demonstrated the positive impact of entacapone on quality of life metrics:
PDQ-39 (Parkinson's Disease Questionnaire-39)
The PDQ-39, a disease-specific quality of life measure, shows significant improvement in:
[@larsen2009]
EuroQol-5D (EQ-5D)
Generic health utility measures also improve with entacapone therapy, reflecting the broad benefits of reduced motor fluctuations.
Beyond standardized measures, patients consistently report:
The use of entacapone in Parkinson's disease has economic implications:
Medication Costs
Entacapone adds to medication costs but may reduce overall healthcare utilization:
[@jorgensen2015]
Cost-Effectiveness
Analyses suggest entacapone is cost-effective when:
Research continues on improved COMT inhibitors:
Opicapone (Ongentys)
Already approved, opicapone represents advancement through:
Diverse Pipeline Candidates
Several additional COMT inhibitors are under development:
[@lewwitt2014]
Future directions include optimization of combination therapy:
| Drug Class | Interaction | Clinical Significance | Management |
|---|---|---|---|
| MAO Inhibitors (non-selective) | Hypertensive crisis risk | Contraindicated | Avoid combination |
| MAO-B Inhibitors (selegiline, rasagiline) | Possible increased effect | Monitor | Usually safe, adjust dose |
| Apomorphine | Enhanced dopaminergic effect | Moderate | May need dose adjustment |
| Cholestyramine | Reduced entacapone absorption | Moderate | Separate by 2-3 hours |
| Iron supplements | Reduced absorption of both | Moderate | Separate by 2-3 hours |
| Methyldopa | Additive hypotensive effect | Moderate | Monitor BP |
| Antipsychotics (typical) | Reduced antiparkinson effect | Significant | Avoid if possible |
| Anticholinergics | Additive anticholinergic effects | Mild | Monitor |
Before initiating entacapone therapy:
| Timepoint | Assessment | Adjustments |
|---|---|---|
| 2 weeks | Efficacy, side effects | Consider dose changes |
| 6 weeks | Motor fluctuations | Optimize levodopa |
| 3 months | Quality of life, dyskinesia | Long-term planning |
| 6 months | Overall response | Annual assessment |
| Annually | Sustained benefit | Continue vs. modify |
New Formulations:
Combination Therapies:
Neuroprotection:
Pharmacogenetics: